Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.41
-0.5%		$15.07
$7.50
▼
$23.29
$971.07M1.081.76 million shs1.83 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-0.52%-5.23%-24.24%-39.79%+61.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
▼
$31.25
$8.32B1.188.78 million shsN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$11.41
-0.5%		$15.07
$7.50
▼
$23.29
$971.07M1.081.76 million shs1.83 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-0.52%-5.23%-24.24%-39.79%+61.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.43
Hold$28.50149.78% Upside

Current Analyst Ratings Breakdown

Latest MLTX and IMGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/21/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/13/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $50.00
8/7/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/20/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$4.27 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.84N/AN/AN/AN/A-82.53%-58.17%11/4/2026 (Estimated)

Latest MLTX and IMGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.9086-$0.84+$0.0686-$0.84N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.23
12.56
12.56

Institutional Ownership

CompanyInstitutional Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%

Insider Ownership

CompanyInsider Ownership
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
5.07%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionNo Data
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
13085.11 million76.26 millionOptionable

Recent News About These Companies

MoonLake Immunotherapeutics Files Biologics License Application for Sonelokimab to Treat Hidradenitis Suppurativa
October 2 at 2:18 PM  |  kalkinemedia.comK
Analysts’ Opinions Are Mixed on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX) and Liquidia Technologies (LQDA)
October 2 at 2:18 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LQDA/pressreleases/4918204/analysts-opinions-are-mixed-on-these-healthcare-stocks-moonlake-immunotherapeutics-mltx-and-liquidia-technologies-lqda/
MoonLake files FDA application for sonelokimab therapy
September 30 at 5:11 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/moonlake-files-fda-application-for-sonelokimab-therapy?utm_source=marketbeat.com&utm_medium=referral
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Now Rated "Moderate Buy" by Wall Street Analysts
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31062231
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rated "Moderate Buy" by Sell-Side Analysts
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-moonlake-immunotherapeutics-nasdaq-mltx-stock-rated-moderate-buy-by-sell-side-analysts-2026-09-29/
Wall Street Zen Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053716
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Bumped Down to Strong Sell by Wall Street Zen
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-moonlake-immunotherapeutics-nasdaq-mltx-stock-bumped-down-to-strong-sell-by-wall-street-zen-2026-09-27/
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Sell at Wall Street Zen
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-moonlake-immunotherapeutics-nasdaq-mltx-raised-to-sell-at-wall-street-zen-2026-09-19/
111,590 Shares in MoonLake Immunotherapeutics $MLTX Purchased by Engineers Gate Manager LP
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-111590-shares-in-moonlake-immunotherapeutics-mltx-purchased-by-engineers-gate-manager-lp-2026-09-15/
MLTX stock on track for worst week since last fall as FDA filing date for skin disease drug draws near
September 11, 2026  |  msn.comhttps://www.msn.com/en-in/health/diseases-and-conditions/mltx-stock-on-track-for-worst-week-since-last-fall-as-fda-filing-date-for-skin-disease-drug-draws-near/ar-AA2c2W70
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 7.7% - Time to Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-moonlake-immunotherapeutics-nasdaq-mltx-shares-down-77-time-to-sell-2026-09-09/
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
September 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943841-moonlake-immunotherapeutics-the-bull-case-does-not-require-clinical-supremacy?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Hold" by Brokerages
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-moonlake-immunotherapeutics-nasdaq-mltx-given-consensus-rating-of-hold-by-brokerages-2026-09-04/
MoonLake Immunotherapeutics (MLTX)
August 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/MLTX/earnings-calls/
MoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’
August 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/moonlake-s-psoriatic-arthritis-drug-shows-promise-in-phase-3-trial-retail-shrugs-off-premarket-slide-says-pipeline-is-intact/ar-AA29M2Fr
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moonlake-immunotherapeutics-q2-loss-narrows-130809814.html
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/moonlake-announces-positive-topline-results-from-the-phase-3-izar-1-trial-of-sonelokimab-in-psoriatic-arthritis-demonstrating-significant-improvements-across-all-clinical-endpoints-and-reports-1036435278
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
August 10, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/08/61084682/moonlakes-psoriatic-arthritis-drug-shows-promise-in-late-stage-study
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
August 10, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/moonlakes-psoriatic-arthritis-drug-meets-key-goals-late-stage-trial-2026-08-10/
MoonLake announces positive Phase 3 psoriatic arthritis results
August 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/moonlake-announces-positive-phase-3-psoriatic-arthritis-results?utm_source=marketbeat.com&utm_medium=referral
MoonLake reports positive Phase 3 PsA data and $537 million cash
August 10, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$11.41 -0.06 (-0.52%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$11.39 -0.02 (-0.17%)
As of 10/2/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas